These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 28877690)

  • 1. Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA.
    Zhao TT; Kim KS; Shin KS; Park HJ; Kim HJ; Lee KE; Lee MK
    BMC Complement Altern Med; 2017 Sep; 17(1):449. PubMed ID: 28877690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gynostemma pentaphyllum Ethanolic Extract Protects Against Memory Deficits in an MPTP-Lesioned Mouse Model of Parkinson's Disease Treated with L-DOPA.
    Kim KS; Zhao TT; Shin KS; Park HJ; Cho YJ; Lee KE; Kim SH; Lee MK
    J Med Food; 2017 Jan; 20(1):11-18. PubMed ID: 28005447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
    Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
    Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of gypenosides on anxiety disorders in MPTP-lesioned mouse model of Parkinson's disease.
    Shin KS; Zhao TT; Choi HS; Hwang BY; Lee CK; Lee MK
    Brain Res; 2014 Jun; 1567():57-65. PubMed ID: 24747613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK
    BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trx-1 ameliorates learning and memory deficits in MPTP-induced Parkinson's disease model in mice.
    Zhang X; Bai L; Zhang S; Zhou X; Li Y; Bai J
    Free Radic Biol Med; 2018 Aug; 124():380-387. PubMed ID: 29960099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
    J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
    Ferro MM; Bellissimo MI; Anselmo-Franci JA; Angellucci ME; Canteras NS; Da Cunha C
    J Neurosci Methods; 2005 Oct; 148(1):78-87. PubMed ID: 15939479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-Dopa restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats.
    Gevaerd MS; Miyoshi E; Silveira R; Canteras NS; Takahashi RN; Da Cunha C
    Int J Neuropsychopharmacol; 2001 Dec; 4(4):361-70. PubMed ID: 11806861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice.
    Yabuki Y; Ohizumi Y; Yokosuka A; Mimaki Y; Fukunaga K
    Neuroscience; 2014 Feb; 259():126-41. PubMed ID: 24316474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a combination treatment of KD5040 and
    Ahn S; Song TJ; Park SU; Jeon S; Kim J; Oh JY; Jang J; Hong S; Song MA; Shin HS; Jung YR; Park HJ
    BMC Complement Altern Med; 2017 Apr; 17(1):220. PubMed ID: 28424060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitrosative and cognitive effects of chronic L-DOPA administration in rats with intra-nigral 6-OHDA lesion.
    Ramírez-García G; Palafox-Sánchez V; Limón ID
    Neuroscience; 2015 Apr; 290():492-508. PubMed ID: 25644418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
    Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.
    Da Cunha C; Angelucci ME; Canteras NS; Wonnacott S; Takahashi RN
    Cell Mol Neurobiol; 2002 Jun; 22(3):227-37. PubMed ID: 12469866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of estrogen and levodopa in 1-methyl-4-pheny-l-1, 2, 3, 6-tetrahydropyridine (mptp)-induced cognitive deficit in Parkinsonian ovariectomized mice model: A comparative study.
    Yadav SK; Pandey S; Singh B
    J Chem Neuroanat; 2017 Nov; 85():50-59. PubMed ID: 28711564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.